0000950170-22-023212.txt : 20221108 0000950170-22-023212.hdr.sgml : 20221108 20221108160955 ACCESSION NUMBER: 0000950170-22-023212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221108 DATE AS OF CHANGE: 20221108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38470 FILM NUMBER: 221368956 BUSINESS ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 416-1192 MAIL ADDRESS: STREET 1: 285 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 8-K 1 ubx-20221108.htm 8-K 8-K
false000146336100014633612022-11-082022-11-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 08, 2022

 

 

UNITY BIOTECHNOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38470

27-4726035

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

285 East Grand Ave.

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 416-1192

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

UBX

 

The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 8, 2022, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Reference is made to the Exhibit Index attached hereto.

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press release dated November 8, 2022.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

UNITY BIOTECHNOLOGY, INC.

 

 

 

 

Date:

November 8, 2022

By:

/s/ Anirvan Ghosh

 

 

 

Anirvan Ghosh, Ph.D.
Chief Executive Officer

 

 EX-99.1 2 ubx-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

UNITY Biotechnology, Inc. Reports Third Quarter 2022

Financial Results and Business Updates

 

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months -

 

- 16-Week Data from Phase 2 ENVISION Study in wet Age-Related Macular Degeneration Expected in First Quarter of 2023 -

 

- As of September 30, 2022, UNITY had approximately $103.9 million in cash, cash equivalents and marketable securities, providing runway into the first quarter of 2024 -

SOUTH SAN FRANCISCO, Calif., November 8, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2022.

 

“In the third quarter, we reported positive results from the Phase 2 BEHOLD study in patients with DME and strengthened our financial resources, which we believe will carry us through key value-driving milestones for our rapidly advancing lead program, UBX1325,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “The impressive 24-week results from BEHOLD demonstrate that a single injection of UBX1325, in addition to showing a favorable safety and tolerability profile, led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters compared to sham treatment, maintained stabilization of retinal structure, and improved the proportion of rescue-free patients compared to the sham-treated arm. These results, together with the growing dataset, position UBX1325 as a potential transformative, first-in-class and best-in-disease therapy, and underscore the opportunity for clinical utility of our senolytic approach. We look forward to further evaluating the durability of treatment effect through 48 weeks with our long-term extension of the BEHOLD study, with data expected in the second quarter of 2023. In parallel, we remain on track to report 16-week data from our Phase 2 ENVISION study in wet Age-Related Macular Degeneration (AMD) in the first quarter of 2023.”

 

 

Upcoming Milestones

•
16-week safety and efficacy data from Ph2 ENVISION study in wet AMD expected in Q1 2023

 

•
48-week long-term extension data from Ph2 BEHOLD study in DME expected in Q2 2023

 

•
Full 24-week safety and efficacy data from Ph2 ENVISION study in wet AMD expected in Q2 2023

 

•
48-week long-term extension study data from Ph2 ENVISION study in wet AMD expected in Q4 2023

Third Quarter Financial Results

Cash, cash equivalents and marketable securities totaled $103.9 million as of September 30, 2022, compared with $64.5 million as of June 30, 2022. UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations into the first quarter of 2024.

Operating loss for the three months ended September 30, 2022, was $13.1 million compared to $14.8 million for the three months ended September 30, 2021. Cash used in operations during the first three quarters of 2022 was $40.7 million compared to $40.0 million for the first three quarters of 2021.

Research and development expenses decreased by $0.9 million, to $8.2 million for the three months ended September 30, 2022 from $9.1 million for the three months ended September 30, 2021. The decrease was primarily due to decreases of $1.7 million in personnel costs due to reduction in force, $0.5 million in laboratory supplies and $0.9 million in facilities-related and other operating costs due to allocation to general and administrative expenses of net expenses on Brisbane and East Grand facilities which have been subleased, offset by $2.2 million increase in direct research and development expenses mainly due to the advancement of UBX1325 studies and increase in CMO and CRO activities during the three months ended September 30, 2022.

General and administrative expenses decreased by $0.8 million, to $4.9 million for the three months ended September 30, 2022 from $5.7 million for the three months ended September 30, 2021. The decrease was primarily due to decreases of $0.6 million in personnel costs mainly due to reduction in force and $0.4 million in professional fees, offset by $0.2 million increase in facilities-related and other operating costs.

 

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

 

Forward-Looking Statements

 

This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of the results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments

will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the Securities and Exchange Commission on November 8, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

 

Unity Biotechnology, Inc.

Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Licensing revenue - related party

 

$

—

 

 

$

—

 

 

$

236

 

 

$

—

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

8,208

 

 

 

9,081

 

 

 

28,222

 

 

 

28,815

 

General and administrative

 

 

4,922

 

 

 

5,747

 

 

 

15,669

 

 

 

17,952

 

Total operating expenses

 

 

13,130

 

 

 

14,828

 

 

 

43,891

 

 

 

46,767

 

Loss from operations

 

 

(13,130

)

 

 

(14,828

)

 

 

(43,655

)

 

 

(46,767

)

Interest income

 

 

329

 

 

 

20

 

 

 

416

 

 

 

82

 

Interest expense

 

 

(866

)

 

 

(792

)

 

 

(2,568

)

 

 

(2,351

)

Other income (expense), net

 

 

(41

)

 

 

(850

)

 

 

49

 

 

 

(996

)

Net loss

 

 

(13,708

)

 

 

(16,450

)

 

 

(45,758

)

 

 

(50,032

)

Other comprehensive (loss) gain

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on marketable debt securities

 

 

(87

)

 

 

—

 

 

 

(230

)

 

 

—

 

Comprehensive loss

 

$

(13,795

)

 

$

(16,450

)

 

$

(45,988

)

 

$

(50,032

)

Net loss per share, basic and diluted

 

$

(1.36

)

 

$

(2.97

)

 

$

(5.77

)

 

$

(9.13

)

Weighted-average number of shares used in
   computing net loss per share, basic and
   diluted

 

 

10,072,076

 

 

 

5,543,644

 

 

 

7,928,729

 

 

 

5,482,648

 

 

Unity Biotechnology, Inc.

Condensed Balance Sheets

(In thousands)

 

 

September 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

22,576

 

 

$

32,905

 

Short-term marketable securities

 

 

76,364

 

 

 

55,170

 

Prepaid expenses and other current assets

 

 

3,234

 

 

 

1,879

 

Restricted cash

 

 

550

 

 

 

550

 

Total current assets

 

 

102,724

 

 

 

90,504

 

Property and equipment, net

 

 

8,202

 

 

 

9,942

 

Operating lease right-of-use assets

 

 

19,515

 

 

 

21,286

 

Long-term marketable securities

 

 

4,980

 

 

 

1,993

 

Long-term restricted cash

 

 

896

 

 

 

896

 

Other long-term assets

 

 

76

 

 

 

91

 

Total assets

 

$

136,393

 

 

$

124,712

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,444

 

 

$

1,985

 

Accrued compensation

 

 

2,961

 

 

 

4,028

 

Accrued and other current liabilities

 

 

4,593

 

 

 

6,370

 

Deferred revenue

 

 

—

 

 

 

216

 

Derivative liability related to debt

 

 

—

 

 

 

963

 

Current portion of long-term debt

 

 

6,776

 

 

 

3,055

 

Total current liabilities

 

 

16,774

 

 

 

16,617

 

Operating lease liability, net of current portion

 

 

27,792

 

 

 

30,094

 

Long-term debt, net

 

 

13,262

 

 

 

18,409

 

Other long-term liabilities

 

 

—

 

 

 

23

 

Total liabilities

 

 

57,828

 

 

 

65,143

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

524,623

 

 

 

459,636

 

Accumulated other comprehensive loss

 

 

(275

)

 

 

(44

)

Accumulated deficit

 

 

(445,784

)

 

 

(400,024

)

Total stockholders’ equity

 

 

78,565

 

 

 

59,569

 

Total liabilities and stockholders’ equity

 

$

136,393

 

 

$

124,712

 

 

 

 

 

Media Contact

Evoke Canale Communications

Jason Spark

jason.spark@evokegroup.com

 

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

 

 

 EX-101.LAB 3 ubx-20221108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 4 ubx-20221108.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 ubx-20221108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document And Entity Information
Nov. 08, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2022
Entity Registrant Name UNITY BIOTECHNOLOGY, INC.
Entity Central Index Key 0001463361
Entity Emerging Growth Company true
Securities Act File Number 001-38470
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 27-4726035
Entity Address, Address Line One 285 East Grand Ave.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 416-1192
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol UBX
Security Exchange Name NASDAQ
XML 7 ubx-20221108_htm.xml IDEA: XBRL DOCUMENT 0001463361 2022-11-08 2022-11-08 false 0001463361 8-K 2022-11-08 UNITY BIOTECHNOLOGY, INC. DE 001-38470 27-4726035 285 East Grand Ave. South San Francisco CA 94080 (650) 416-1192 false false false false Common Stock, par value $0.0001 per share UBX NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports ubx-20221108.htm ubx-20221108.xsd ubx-20221108_lab.xml ubx-20221108_pre.xml ubx-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ubx-20221108.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ubx-20221108.htm" ] }, "labelLink": { "local": [ "ubx-20221108_lab.xml" ] }, "presentationLink": { "local": [ "ubx-20221108_pre.xml" ] }, "schema": { "local": [ "ubx-20221108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ubx", "nsuri": "http://unitybiotechnology.com/20221108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ubx-20221108.htm", "contextRef": "C_e7128e4b-2ffc-49a8-92fe-e592215ae306", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ubx-20221108.htm", "contextRef": "C_e7128e4b-2ffc-49a8-92fe-e592215ae306", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitybiotechnology.com/20221108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0000950170-22-023212-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-023212-xbrl.zip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